Trial Profile

Phase I/II, Open Label, Multicenter Study of Rapcabtagene Autoleucel in Adult Patients With CLL/SLL, 3L+ DLBCL, r/r ALL and 1L HR LBCL

Status: Recruiting

Phase of Trial: Phase I/II

Latest Information Update: 02 Mar 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Ibrutinib (Primary) ; Rapcabtagene autoleucel (Primary)
Indications Chronic lymphocytic leukaemia; Diffuse large B cell lymphoma; Precursor cell lymphoblastic leukaemia-lymphoma
Focus Adverse reactions; First in man; Therapeutic Use
Sponsors Novartis Pharma A.G.; Novartis Pharmaceuticals

Most Recent Events

25 Nov 2024 According to a Novartis media release, data from this trial will be presented at the 66th American Society of Hematology (ASH) Annual Meeting.
07 Oct 2024 Planned End Date changed from 30 Jun 2027 to 31 May 2028.
08 Mar 2024 Planned number of patients changed from 225 to 240.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com